Friday’s ETF To Watch: Health Care SPDR (XLV)

With health care remaining a major issue in today’s political and financial world, big pharmaceutical firms have been under the microscope for some time. Legislation earlier this year from Washington created quite a buzz, as the bill executed an overhaul of our entire health care system. On top of this, many big pharma firms who have been coasting along with their big name drugs, are fast approaching a patent cliff, suggesting that some of their most popular drugs– and important revenue streams– are likely to disappear as they go generic in the coming years. When this happens, it could be a very difficult time for the pharmaceutical industry which makes the time before the cliff all the more important as companies scramble to shore up their product lines and get their balance sheets in order before their products lose their patent protection [see also Is Your Biotech ETF A Leader [...] Click here to read the original article on ETFdb.com. Related Stories: Beyond XLV: Five Alternative Health Care ETFs Israel ETF (EIS): An Unlikely Winner In Health Care Reform Health Care ETFs In Focus After Historic Vote